How UnitedHealth Should Give A Boost To Walgreens' 2017 Guidance
Credit Suisse foresees an acceptable 2017 earnings per share guidance from Walgreens Boots Alliance Inc (NASDAQ: WBA) when its releases its results on Thursday. The opinion follows strong quarterly results reported by pharmacy benefit manager UnitedHealth Group Inc (NYSE: UNH).
Analyst Robert Willoughby sees the 12 percent increase in UnitedHealth's OptimumRx adjusted scripts as a positive for Walgreens given that the latter is UnitedHealth's preferred provider of 90-day prescriptions. The analyst noted that UnitedHealth's total healthcare membership rose 4.4 percent year-over-year to 48 million lives, with Medicare and Medicaid lives rising 8.4 percent and 9.1 percent, respectively.
Credit Suisse clarified that its earnings per share forecast for Walgreens does not include contribution from Rite Aid Corporation (NYSE: RAD)'s stores starting in January, Rite Aid's PBM business or any deleveraging or refinancing efforts.
The firm noted that its model also doesn't include a UnitedHealth contribution or anything from its other deals across the supply chain. Additionally, Walgreens' role as the anchor pharmacy in Express Scripts Holding Company (NASDAQ: ESRX)'s Diabetes Care Value Program is not included, the firm noted.
Concluding, Credit Suisse said it may be difficult for Walgreens to guide to the high end at this juncture, given a host of variables in play. That said, the firm said it would revisit its $4.85 per share estimate when more clarity emerges.
As such, Credit Suisse has an Outperform rating and $95 price target on the shares of the company.
At time of writing, shares of Walgreens were down 1.43 percent at $76.96.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email firstname.lastname@example.org with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for ESRX
|Nov 2016||Deutsche Bank||Upgrades||Sell||Hold|
|Oct 2016||UBS||Initiates Coverage on||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.